<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383081</url>
  </required_header>
  <id_info>
    <org_study_id>SCLnow-XY-02</org_study_id>
    <nct_id>NCT03383081</nct_id>
  </id_info>
  <brief_title>The Safety/Efficacy of hUC Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis</brief_title>
  <official_title>A Clinical Research on the Safety/Efficacy of Human Umbilical Cord Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sclnow Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sclnow Biotechnology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is verify the efficacy and safety of Human Umbilical Cord&#xD;
      Mesenchymal Stem Cells (UC-MSC) therapy for patients with Osteoarthritis, and in addition,&#xD;
      provide basis for exploring the treatment regimen of UC-MSC therapy in different degree of&#xD;
      cartilage defect disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a random, open label, and parallel controled experiment. All patients are selected&#xD;
      and sign consent forms, then divided into 3 groups. Doctors collect the basic information of&#xD;
      patient. All patients receive laboratory and image examination as baseline. Then, they will&#xD;
      give cell treatment based on the clinical protocol. Doctors have follow-up visit on 2 weeks,&#xD;
      1, 2, 3, 6, and 12 months after treatment, and do safety and efficacy evaluation.&#xD;
&#xD;
      Safety evaluation. Researcher collect all examination data of patients and compare with each&#xD;
      groups. The safety tests including blood routine, urine routine, hepatorenal function, C&#xD;
      reactive protein, erythrocyte sedimentation rate, and tumor marker, etc.&#xD;
&#xD;
      Efficacy evaluation. Based on Lysholm, the international knee documentation committee (IKDC)&#xD;
      knee evaluation form, and Visual Analogue Scale/Score (VAS) to examine the change/improvement&#xD;
      of knee joint function. By Magnetic Resonance Imaging (MRI) examination, grade patients with&#xD;
      Kellgren-Lawrence Grading Scale, Assessment of Preoperative Cartilage Defect Severity&#xD;
      (AMADEUS), and observe the change/improvement of patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kellgren-Lawrence Grading Scale</measure>
    <time_frame>12 months</time_frame>
    <description>Using Magnetic Resonance Imaging (MRI) examination, and based on the images of bilateral knee joint, grade by Kellgren-Lawrence Grading Scale. Kellgren-Lawrence Grading Scale is a method of classifying the severity of knee osteoarthritis (OA).&#xD;
Grade 0: No radiographic features of osteoarthritis; Grade 1: Possible joint space narrowing (normal joint space is at least 2 mm at the superior acetabulum) and osteophyte formation; Grade 2: Definite osteophyte formation with possible joint space narrowing; Grade 3: Multiple osteophytes, definite joint space narrowing, sclerosis and possible bony deformity; Grade 4: Large osteophytes, marked joint space narrowing, severe sclerosis and definite bony deformity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Preoperative Cartilage Defect Severity (AMADEUS)</measure>
    <time_frame>12 months</time_frame>
    <description>Using Magnetic Resonance Imaging (MRI) examination to diagnose patients by Assessment of Preoperative Cartilage Defect Severity (AMADEUS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lysholm scoring</measure>
    <time_frame>12 months</time_frame>
    <description>Using Lysholm Knee Scoring Scale to grade the knee function of patients, and examine the changes or improvement compare to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The international knee documentation committee (IKDC) knee evaluation form</measure>
    <time_frame>12 months</time_frame>
    <description>The international knee documentation committee knee evaluation form is used to assess the knee function of patients, examine the changes or improvement compare to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale/Score（VAS）</measure>
    <time_frame>12 months</time_frame>
    <description>Using Visual Analogue Scale/Score for pain to examine the change/improvement of knee joint function.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Low dose mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control groups</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low dose mesenchymal stem cells</intervention_name>
    <description>Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 * 10^7 cells (5ml);</description>
    <arm_group_label>Low dose mesenchymal stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dose mesenchymal stem cells</intervention_name>
    <description>Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 * 10^7 cells (5ml)</description>
    <arm_group_label>High dose mesenchymal stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intraarticular injection</intervention_name>
    <description>Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group</description>
    <arm_group_label>High dose mesenchymal stem cells</arm_group_label>
    <arm_group_label>Low dose mesenchymal stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Knee Osteoarthritis by Kellgren and Lawrence Grading Scale, classified&#xD;
             with Grade 2-3&#xD;
&#xD;
          -  Confirm with cartilage injury,articular cartilage part or full-thickness injury, by MR&#xD;
             (Magnetic Resonance)&#xD;
&#xD;
          -  Age &lt;70, no serious organ dysfunction&#xD;
&#xD;
          -  Over 2 years knee pain or no very effective with conservative treatments&#xD;
&#xD;
          -  Knee pain of VAS (visual analog scale score) is 4 or higher&#xD;
&#xD;
          -  Normal hepatic and renal function, no history of gout, rheumatoid arthritis, and&#xD;
             autoimmune diseases, etc.&#xD;
&#xD;
          -  Understand and sign the consent form of this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refuse to sign the consent form, or cannot keep follow-up visit&#xD;
&#xD;
          -  Age &gt;70; Age &lt;70, but with multiple organ failure&#xD;
&#xD;
          -  Unstable vital signs (breath, blood pressure, pulse)&#xD;
&#xD;
          -  Combined with knee ligament (anterior and the posterior cruciate ligament, medial and&#xD;
             lateral collateral ligament) rupture, laxity, etc.&#xD;
&#xD;
          -  Serious bleeding tendency, poor coagulation function (PTA &lt;35%)&#xD;
&#xD;
          -  Pregnant or breast feeding women, or positive pregnancy test in 7 days before&#xD;
             treatment&#xD;
&#xD;
          -  Participate other clinical experiments in 3 months&#xD;
&#xD;
          -  With progressing malignant tumor&#xD;
&#xD;
          -  Combined with shock and critically ill patients&#xD;
&#xD;
          -  With mental disease, cannot&#xD;
&#xD;
          -  With history of knee joint infection, surgery, and radiotherapy&#xD;
&#xD;
          -  With immunosuppressive agents treatment in 6 weeks&#xD;
&#xD;
          -  Injection with hormones and sodium hyaluronate in joint in 3 months&#xD;
&#xD;
          -  Overweight expressed as body mass index (BMI) &gt;35&#xD;
&#xD;
          -  With skin disease around knee joint&#xD;
&#xD;
          -  With Immunodeficiency disease, including long term use immunosuppressive agents&#xD;
             patients&#xD;
&#xD;
          -  Combined with serious infection&#xD;
&#xD;
          -  With some other conditions that doctor propose not to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongbin Lv</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Guo</last_name>
    <phone>861064368977</phone>
    <email>georgeguo@sclnow.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongbin Lyu</last_name>
      <phone>13126966160</phone>
      <email>michaelliang@sclnow.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis, mesenchymal stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

